Agenda1 Blog

Why does all this matter?

This blog post is the final instalment of a three part series in which Ian Siragher the Business Development Director of Agenda1 Analytical Services has compared the structure of two types of organisation, CAT groups & Boss Companies and tried to unravel what characteristics they display. If this is the first time you’ve visited the blog click here to read part one

Having been involved firstly in banking (LloydsTSB), then for the last 10 years in the R&D arena, currently as a director of Agenda 1 Analytical Services, I have had the chance to observe hundreds of businesses. These observations have coalesced over time whilst reflecting on many of the successful and less successful businesses I have seen. It is my observation that the failures (defined as having failed to see their product successfully sustained in the market place) display many CaT characteristics, whereas the success stories are more likely to display Boss characteristics.

I also feel the distinction is important because CaT businesses can damage the product development market because:

They distort the market for investor funds; by being high risk the cost of capital for all R&D businesses (CaT and Boss) is similarly high.

They distort the way infrastructure is developed and used. Traditional Scientific Incubator units have been developed to support the CaT business model, and this can encourage the profligate use of resources and the garnering of equipment, staff, and resources in the face of more Boss like (virtual business) models.
They disrupt the flow of discovery and invention. Distracting great scientists and research teams by encouraging them to spin out into new companies is arguably a great disservice. Force fitting inventors into the suits of entrepreneurs, requiring them to become business people, robs academia, students and universities of key resources.

They distort how universities approach commercialization.  The technology commercialization model, sees universities who believe in it focussed on maintaining a large percentage of  ownership and seeking a lion’s share of the revenue, arguing that without the discovery there would be no business. The technology is the starting point.  Smart university IP teams will be more flexible, recognising that it is just as arguable that without the business there will be no technology. Such teams will make smarter deals, apparently accepting lower royalties, but balanced against the lower risks that come with a Boss approach.

I have proposed here a black and white world of two types of businesses, but of course the world is not that simple. My intention is to spark a debate. I offer a measure against which any interested party can assess their own, or other businesses and decide if my thoughts are of value. I have deliberately cited no examples or case studies because the devil is always in the detail and any generalized assertion that Business A is “CaT” or “Boss” is a distraction from the intention, which is to offer a hypothesis, I ask interested parties to test the ideas.

Finally, the views are personal to me and do not necessarily reflect the views of colleagues within the Agenda 1 group.

 

 

 

What’s The Difference?

This blog post is the second in a three part series in which Ian Siragher the Business Development Director of Agenda1 Analytical Services compares the structure of two types of organisation, CAT groups & Boss Companies.

As I outlined in my previous blog post (Business Isn’t Rocket Science) companies that focus on the Business of Science, (below I refer to them as Boss Businesses), work very differently to those Commercializing a technology (CaT groups).  One key difference is the different emphasis placed on preparing the entire business to meet the harsh realities of the commercial world.  This distinction is important because, in my opinion, Boss Businesses have a much greater chance of survival and commercial success.


The leadership differs.

CaT groups are often lead by the inventor. There are examples where such leaders turns out to be great businessmen. But there is usually a reason why a University Professor is a University Professor, it is the life they wanted trained for, and enjoy. That is the reason they didn’t become accountants, serial entrepreneurs, venture capitalists, marketing and PR specialists etc, they didn’t want to. A Boss company will be lead from very early on by people who have specialized in business, not people whose claim to company leadership is they “Understand the Technology”. Those who understand the technology have critical roles to play in understanding how the technology could be applied, but they should not make the final business decision as to how they will be applied.

 

The focus of the technology application differs.

A CaT organization has 10 new ideas before breakfast, the teams are creative, excited by change and ever alive to the possibilities.  With Boss Companies the unique benefit of the product are the core focus. The role of the business is to find a way to make those benefits available to the market as quickly and as profitably as possible.  Other bright possibilities are not allowed to distract.

 

CaT specialists lead, Boss specialists support

CaT Groups  thrive on having high quality specialists as part of the team, each niche area of the technology often benefiting from its own leader.  This has a snowball effect, typically that specialism is not required 100% of the time, the specialists by their very nature seek additional tasks to fill their time  – these are not lazy people. Interesting areas for exploration will be identified by them, proposed, championed and followed. This is wonderful and creative, and highly chaotic.. and has no place in a Boss Business. A Boss company uses more sub contractors, consultants and temporary staff  than a CaT group, this helps them maintain focus, specialists are employed to advise on key issues, but are less likely to initiate brand new projects.

 

The Business of Science does not to chase grant revenue

I do believe that start up grants make some sense, and R&D grants which extend the reach of investor funds also have  a part to play. However, there is nothing like revenue from real customers (or lack of it) to tell you if your business idea is a winner. Focus on generating revenue from customers who have options and who are pre-disposed not to buy from you is fundamentally more business oriented than submitting applications to grant bodies who reason for being is to pay the cash out.  A CaT group then is one where the primary revenue stream for more than 3-4 years is grant revenue. Such a business is in reality playing a shell game and even they don’t know where the real value is. Typically there is a lack of a direct correlation between the grant money and unequivocal value generated, and this is a fatal flaw. Boss Companies will find ways to generate revenue, be it from conferences, license fees, feasibility studies, consultancy, or numerous other devices which validate their idea and show that real value is being generated. I would also argue that it must be customers) (plural), CaT groups with a single client are not true businesses, merely differently funded subsidiaries whose existence depends on the decisions of Boards they cannot control.

 

There is one type of  CaT group which falls between these stools, that is the company which successfully  completes numerous funding rounds, without ever generating profits during that period. I would  agree that  these are companies who understand the Business of Science very well, but maybe not entirely  which business they are in!

 

Boss Companies measure their return on capital,  CaT groups measure their capital. 

Boss Companies see ownership of assets as a last resort, every £ tied up in hard capital is a nail in the coffin of return on capital. Boss Companies demands that assets are only purchased when doing so makes fundamentally better business sense than out sourcing, sub contracting, or doing without.  CaT groups retain the operating DNA of their usual forebears, University Departments.  Until recently University Departments   measured success primarily in the acquisition of equipment, facilities, and resources. That is changing, but CaT groups can be identified by this same trait.

 

Boss companies have multiple marketing routes, CaT groups favour published papers and posters.

Posters and papers have a part to play in the marketing mix, they can help some customers make buying decisions. But where an organization’s primary publicity focus is the use of academic publications/conferences to a broadly academic audience then that group cannot claim to be focussing on the Business of Science. Those publications/conferences, bound by convention and rooted in a academic process can be wonderfully written, providing genuine insight, and excite awe. But at their heart they are about publicising the writers/authors/the science but  not the business. So, unless their place with the sales process is completely understood and planned they are almost always a distraction from the true Business of Science.

 

Boss companies compete with competitors, CaT groups  compete internally

Boss companies usually have clear hierarchies and decision making processes. Decision making might still be  messy and inefficient and won’t always come up with the right decision – often there is no “right decision” -  just an opinion of what seems best.  Such businesses are though usually focussed on deciding the way to solve a business problem and achieve a clearly defined goal.

 

In CaT groups the pursuit of scientific truth, of the “right” answer, gets in the way. The academic world is one where knowledge is indeed power, where the ultimate goal is to find the truth and where it is perfectly correct to cling stubbornly to ideas until they are demonstrably shown to be incorrect. This is the very strength of science and crucially important. Business, like politics though is the art of the possible, of compromise.  It is often necessary to make judgements on incomplete facts, to accept that your great idea, your better mousetrap, your beautifully designed solution, is just not going to be adopted. In which case the team have to disagree and get on with the new route. That requirement is very hard for overtly science focussed teams (CaT groups) to accept, the measure of those following the Business of Science is how well they handle this dilemma.

 

Boss teams think more strategically than CaT groups.

CaT groups often take decisions that appear tactical but become strategic bottlenecks.  A CaT group focussed on a technology will make decisions that suit primarily the needs of the group in a semi personal relationship with the technology. A typical example is establishing critical infrastructure in high cost areas close to the development team, rather than in low cost areas the development team might have to move to temporarily. A fixed high cost infrastructure that was easier to manage for a few years by being convenient becomes a long term liability once the technology is working and cost reduction is the goal.

Business Isn’t Rocket Science

This blog post is the first in a three part series in which Ian Siragher the Commercial Director of Agenda1 Analytical Services provides some thoughts & analysis on what he feels is  the difference between commercialising a technology and the “business of science”.

Business isn’t rocket science. A business identifies a product, sources it, one way or another, tells  customers about it, agrees a price, delivers the product, collects the cash covers the costs (hopefully) and starts again. There are plenty of challenges, and plenty of surprises along the way, but usually those surprises and challenges fall into the category of “known unknowns”.

Science on the other hand if not exactly rocket science every time, is science. Science begins with unknowns and works to identify hidden truths. Those truths can be the foundation of great products. But the path from thought to delivery is always difficult.  At the early stages, the customer, product, price, delivery mechanism, cash availability, etc etc are all unknown; the unknown unknowns outweigh the businessperson’s unknowns 10 to 1.

Given those challenges the wonder is that any new technology reaches the market place. And it’s not getting easier. Competition is harder, markets are changing faster, regulations are getting tougher,  and the funding streams are drying up.  Commercializing a technology is just plain hard.

Actually, I dislike the phrase “commercialising a technology”. I dislike it because it focuses on the technology rather than the business. Bringing a technology to thrive successfully in a market place requires focussing on what I see as the Business of Science, not the commercialization of a technology.

I contend that companies that focus on the Business of Science, (later I refer to them as Boss Businesses),  make different decisions, work differently, and have a different mind set to those Commercializing a technology (CaT groups).  The key difference is the different emphasis placed on readying the entire business to meet the harsh realities of the commercial world.  This distinction is important because I believe Boss Businesses have a much great likelihood of survival and success…

The second part of this blog post ‘What’s the difference?’ will be available on this Analytical Science Blog in January. You can follow @Agenda1Blog on twitter for the latest updates from Agenda 1 Analytical Services.

Bringing Science back to the Science Park

The Agenda 1 Blog is now on twitter @Agenda1

In June 2006 an era ended, not many noticed, but it was life changing for those involved. A company that had once employed 60 people on the Listerhills Science Park, Bradford closed.

That business, Nektar Therapeutics UK Ltd, had been at the forefront of developing a new technology, and had state of the art manufacturing capabilities, including a “clean room” for drug product manufacture.

I still remember the frustration I felt as £1m pounds worth of investment was ripped out to meet the landlords (quite correct) requirements to return the premises to their original condition. A necessary step – but a great loss to the Bradford Area in terms of capabilities – the next such facility is probably 50 miles away.

So, 60 science jobs lost, facilities removed, and empty offices – a discouraging sight in  September 2006 when Agenda 1 opened for business – using some of the remaining facilities of Nektar as our base.

Since then we’ve been working away trying to bring Science back to the science park. Actually, we’ve been working away to develop a business, a side effect has been to bring the science back!  Recently articles appeared in the Yorkshire Post & Bradford Telegraph & Argus as testimonies of our success.

We started in 2 units, and now have 4, not quite the 10 that Nektar had, but getting there, we’re also about 30% of the way there as far as people numbers are concerned, and in total we’ve invested around £500,000 in new equipment and additional people to set up and run that equipment – so a scientific phoenix is arising from the ashes.

Of more importance than the equipment, is the range of applications we’ve been involved in. With nearly 100 clients coming through the doors since we started we’ve met far more varied challenges than we ever expected, looking through our archives I see:

- Work involving “Green Solvents”, where we demonstrated that micro-organisms living in soil “polluted” with these solvents not only were unharmed, but seemed to thrive on it!

- Have become experts in everything related to the analysis of Bone Substitute material – the most regularly employed surgical product in the world – which we knew nothing about 5 years ago.

- Developed a method to measure the surface area of the aluminium flakes that make silver paint “silver”.

- Helped a flour mill resolve and argument with a supplier over the effectiveness of their milling equipment

- Measured the size of particles of material suspended in river water, to test the effectiveness of a pumps filtering system

- Developed a way to test if a wound gel used by surgeons really did act as a microbial barrier.

And  many more! In looking at that list I see that our vision and expectation that we would become a pharmaceutical testing laboratory hardly gets a look in here. In that list I’ve even forgotten that we’ve also developed a world leading solubilisation screen now used by companies from around the world as a first step in developing new drug products!

So we might not quite have got the sheer science scale back to where it was in 2006, but now I reflect on it, I think we can honestly say, we have brought the science back to the science park…now about those other 6 units!

Why we should avoid R&D becoming a pain in the AS (Analytical Science)

Every now and then I get asked how we came up with the Lab Timeshare concept which has recently received quite a bit of media coverage including in Lab Bulletin and the Bradford Telegraph & Argus. When asked about the concept, I feel the urge to go into story telling mode… so here we go…

In June 2005 the company I worked for ceased operations. That company had been developing a revolutionary drug manufacturing technology based on Supercritical fluids. The technology still works and only a few days ago a new patent was granted for a product enabled by that technology, it was only the company that ceased to exist.

So how is it that my former employers are now no more than a section on the CV’s of some very bright scientists, and a ruefully remembered tax loss for the investors?

It shouldn’t be so.. a team was in place, further products planned, the knowledge and the science were there, a commercial scale plant stood ready for installation. Then the cash ran out and the company closed.

When faced with a business issue I recall one of my early mentors saying to me “what you’ve described is a symptom of a problem, now tell me the cause”

Perhaps uniquely, cash running out is a symptom and a cause. So why did my employer run out of cash? One of the reasons was because we loved science, and a new technology brings the opportunity of double the science.

Firstly you have the Research work – you need pilot plants, test rigs, laboratory space and so much more, and then you have to analyse what the test systems make, so you need a whole second scientific endeavour – Analytical Science.

Not only did we pour cash into our core Research and Manufacturing. We also poured cash into laboratory space, support overheads, analytical scientists, and a myriad of other systems which, in the clear light of a redundancy notice, I now see we didn’t absolutely need. We could have sourced work much more cash effectively. Our strategy added around 45% to our staff numbers, and the lab space we needed, which translates to adding about 60% to our cash outflow.

I often wonder how much extra time some of that 60% would have gained us – another 3 years perhaps? And of course that would have been in time as well as cash, but also in management effort, shifted from the lab set up and running work, back onto our core technology.

That is one of the reasons we introduced Lab Time Share. A way for start up businesses and established companies to focus on their business while we do the science. As the Business of Science gets more and more challenging, I’m convinced that well aligned but disparate groups, all working to their own agenda, but with a shared scientific goal are the way forward.

What a difference an array makes!

XRD is a great technique for understanding crystalline structure and even elemental ratios in products, but it has it’s operational limitations. A limiting factor is that in order to be confident in the output it is necessary to achieve a certain “peak intensity” in the analysis. Peak intensity is determined  primarily by  “dwell time”, the length of time a measurement is taken for any given area of the sample. Long story, short – to achieve a satisfactory peak intensity (say 4000) usually take around 30 minutes per sample.

So, working out the maximum number of samples that can analysed in a working day is pretty easy.

9 samples in a holder take 4.5 hours, allow 30 minutes to take samples off and put new ones on, and in 8 hours you can make two runs, so in a working day that’s just 18 samples. But of course if you put the first 9 on at 8.00am, the next on at 1.00pm and the last on at 5.30 then you can squeeze 27 samples into a “working day” of 9 ½ hours.  Which is fine as long as you don’t have clients needing longer than 30 minutes runs, or more than 27 samples in a day! So when we were faced with both those challenges  issues, we had to identify how to solve the problem, and we were quite clear this is our problem, not the client’s – who quite rightly just wants the data!

Shift systems can give an initial boost in capacity, but are not really a sustainable approach, and in any event it could work out expensive for us in the long term (and therefore the client).

Increasing the number of samples in the sample holder, so that we could run all night, offered an option. However,  that changed the sample size (and therefore the controlled method we use) and the electronics of  our cGMP controlled Bruker D8 XRD kit. Neither change was something we would want to leap into, and the nature of such changes is that they are time consuming, so not a sensible option.

The we considered the Bruker “Lynx eye” attachment to our detector. This is an array of 192 detectors rather than just 1. This allowed much more of the data from different parts of the sample to be collected in a single run. In theory a ½ hour run could be reduced to a few minutes and still reach the required peak intensity.

In discussion with Bruker we agreed this was the right approach, and instigated the change over a 6 week period (from first discussion to delivery and installation).  On the first use we found a 6 minute run time produced a peak intensity of over 20,000 – well above our target level. We’re now establishing the precise dwell time we need. The bottom line is that we’ve increased our capacity from around 30 samples a day to over 100. That gives us both the greater capacity and the cover we need for routine servicing and other operational issues.

Just goes to show, “it ain’t what you do, it’s the array that you do it (with) .. er sort of!